Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY - Get Free Report) was the recipient of a large drop in short interest in the month of March. As of March 31st, there was short interest totalling 53,600 shares, a drop of 53.2% from the March 15th total of 114,600 shares. Based on an average daily volume of 325,600 shares, the short-interest ratio is currently 0.2 days. Approximately 0.0% of the company's shares are short sold.
Chugai Pharmaceutical Trading Up 2.9 %
OTCMKTS:CHGCY traded up $0.85 during trading hours on Monday, hitting $29.73. 157,032 shares of the stock traded hands, compared to its average volume of 224,932. The firm has a market cap of $97.84 billion, a price-to-earnings ratio of 38.61 and a beta of 0.80. The firm has a 50 day moving average price of $23.74 and a 200 day moving average price of $22.81. Chugai Pharmaceutical has a fifty-two week low of $14.52 and a fifty-two week high of $30.72.
Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) last released its quarterly earnings data on Thursday, January 30th. The company reported $0.18 earnings per share for the quarter. Chugai Pharmaceutical had a net margin of 33.07% and a return on equity of 21.53%. Research analysts predict that Chugai Pharmaceutical will post 0.74 EPS for the current year.
About Chugai Pharmaceutical
(
Get Free Report)
Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.
Read More
Before you consider Chugai Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chugai Pharmaceutical wasn't on the list.
While Chugai Pharmaceutical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
